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Cells are complex systems that regulate a multitude of
biologic pathways involving a diverse array of mol-
ecules. Cancer can develop when these pathways be-
come deregulated as a result of mutations in the genes
coding for these proteins or of epigenetic changes that
affect gene expression, or both 1,2. The diversity and
interconnectedness of these pathways and their mo-
lecular components implies that a variety of mutations
may lead to tumorigenic cellular deregulation 3–6. This
variety, combined with the requirement to overcome
multiple anticancer defence mechanisms 7, contributes
to the heterogeneous nature of cancer. Consequently,
tumours with similar histology may vary in their un-
derlying molecular circuitry 8–10, with resultant differ-
ences in biologic behaviour, manifested in proliferation
rate, invasiveness, metastatic potential, and unfortu-
nately, response to cytotoxic therapy. Thus, cancer can
be thought of as a family of related tumour subtypes,
highlighting the need for individualized prediction both
of disease progression and of treatment response, based
on the molecular characteristics of the tumour.
HIGH-THROUGHPUT TECHNIQUES AND
APPROACHES
The development of high-throughput technologies that
assess the expression of messenger RNA (mRNA) tran-
scripts (“gene expression profiling”) has profoundly
changed the fields of biology and medicine. By provid-
ing a snapshot of active cellular pathways, expression
profiles can provide a more comprehensive picture of
the biologic nature of a given tumour than can conven-
tional clinical and pathologic indicators alone 11.
These profiles have been put to progressively more
sophisticated uses 12–14. The discovery that expres-
sion profiles could be used to distinguish between dif-
ferent tumour types 15 was followed by the discovery
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of subclasses of various cancers with distinct patterns
of gene expression, 9 some of which had implications
for survival 8,10,16. Those discoveries were closely
followed by the development of prognostic prediction
models, which have been used to predict disease pro-
gression or relapse in the absence of cytotoxic ther-
apy 11–14. The relative expression levels of a select
number of mRNA transcripts in these models can help
to determine whether a patient should be treated. A
good prognosis means that treatment can be avoided,
and a poor prognosis suggests that further action is
warranted. This approach minimizes the burden of
treatment and maximizes the benefit to treated pa-
tients. As a demonstration of the utility of this tech-
nology, some of these models have been developed
into diagnostic assays for use in the clinic 12,13,15–24.
Work is currently under way to generate similar pre-
dictors for tumour response to anti-neoplastic thera-
peutic regimens based on the gene expression signature
of the individual tumour.
A classical approach to the development of these
response predictors is to accrue patients in clinical
trials, to profile the gene expression of individual tu-
mours with microarrays, to discover biomarkers dif-
ferentially expressed in patients responding and not
responding to treatment, and then to generate predic-
tion models that distinguish non-responders from re-
sponders. This approach is straightforward, but it
suffers from several limitations, the most significant
of which is that testing and monitoring patients un-
dergoing each therapeutic regimen is extremely costly,
slow, and limited to a very small number of current
therapeutic options. Also, using this technique to gen-
erate successful prediction models for a particular
drug, or its novel combinations, will be difficult, be-
cause trials using monotherapy and the numerous novel
combinations are restrictive and reserved to phase I–
II designs. Predicting the efficacy of multiple drugs
has been described 25–27, but this approach suffers
from the significant limitation that such models can
be used only for the specific combinations—in effect
preventing the combinatorial use of agents in other
ways. This latter limitation is particularly relevant
because many current clinical trials are evaluatingWILLIAMS et al.
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novel anti-neoplastic drugs that could ultimately be
used in combination with current agents.
Recent advances by our group and others have pro-
vided a potential solution to this problem. The National
Cancer Institute (NCI) has tested hundreds of thousands
of potentially therapeutic compounds on a panel of 60
cell lines (NCI–60) 28 profiled using microarrays 29. Sen-
sitivity data, in the form of GI50 values (the concentra-
tion that inhibits the growth of the cell line by 50%), are
publicly available for approximately 45,000 compounds.
We 30,a and others 31–33 have developed approaches to
harness these data to generate predictions for the re-
sponse of individual tumours to particular drugs.
CO-EXPRESSION EXTRAPOLATION AND
APPLICATION
Here, we describe our previously demonstrated
method, the co-expression extrapolation (COXEN) tech-
nique 30, with its potential for the development of
therapy response biomarkers without the limitations of
the conventional approach described earlier. For each
drug evaluated on the NCI–60 assay, we can compare
the expression patterns of sensitive and resistant cell
lines to discover biomarkers and patterns of expres-
sion that correspond with drug sensitivity. For multiple
reasons (such as inherent differences in environment
and tissue type, and simple biologic variability), a gene
may be differentially regulated in cell lines than in
human tumours, and so we therefore determine which
genes are concordantly expressed between the cell line
panel and a set of human tumour microarray data. This
step filters out uninformative or spurious genes. By
focusing on the concordantly regulated genes, we can
use a small number of biomarkers to make predictions.
Using this method, we can also generate prediction
models without intermingling data from training and
test patient sets in any manner—a situation that should
be avoided. 34
Validation of this and other techniques is of key
importance before any prediction model can be used
clinically. Prospective clinical trials may be important
for such validation, but extensive banks of formalin-
fixed paraffin-embedded (FFPE) tissue samples may
also serve as a key resource for retrospective valida-
tion of these models 35, which if sufficiently robust
and generalizable, may be sufficient for clinical use.
Biomarker evaluation on prospectively collected tu-
mour tissues from patients enrolled in clinical trials
that have been completed are particularly valuable 19.
Because the COXEN technique can generate prediction
models requiring assessment of the expression of rela-
tively few genes, quantitative polymerase chain reac-
tion testing of FFPE tumour tissues can be used to
determine a “predicted response” score, which can then
be compared with the actual response of the patient to
assess the accuracy of the predictions. Additionally,
promising new technologies may enable high-through-
put gene expression profiling of FFPE tissues themselves,
facilitating assessment of the levels of many more
genes 36. It is also important to note that any predicted
probabilities of response will be relative and not abso-
lute; a patient with a higher predictive score will be
more sensitive to a compound than one with a lower
predictive score for the same compound. Therefore,
during the process of validation, it will also be impor-
tant to explore how prediction scores translate into real-
world effects—namely, how differences in the COXEN
score translate into differences in patient outcomes and
whether those differences are clinically significant.
Once validated models are developed, the COXEN
technique will have wide application. Validated mod-
els for several different treatment regimens used on a
particular type of tumour can guide an oncologist to-
ward selection of the optimal treatment for a specific
patient. Validated models can also be used to predict
response for tumours of particular tumour histology to
U.S. Food and Drug Administration–approved drugs that
have not previously been used to treat that particular
tumour. This approach may prove very useful for pa-
tients with rare disease types or failure on established
treatment regimens and for whom no clear guidelines
exist for salvage regimens. These models can also be
used to increase the likelihood that a novel drug will be
found efficacious in clinical trials through the selec-
tive accrual of patients who are predicted to respond to
the drug by virtue of analysis of their tumour.
Importantly, the COXEN technique has shown some
promise in drug discovery and thus may also be used
in the future to prioritize drug leads: after screening
newly synthesized drugs on cell-line panels, estimates
can be made about the effectiveness of treatment.
Another important application is the use of this tech-
nique for drug “repositioning” or “salvage,” which may
offer significant new applications for agents that have
already been studied in clinical trials, but whose target
cancer populations may not have been optimally iden-
tified in the past.
However, much work remains to be done on the
development and validation of these genomic drug re-
sponse predictor models. Most chemotherapy regimens
involve drugs administered in combinations, and there-
fore future work should devote particular attention to
prediction of responses to these combination regimens.
The individual and synergistic effects of the single com-
pounds must also be understood so as to refine combi-
nations for greater effectiveness and reduced toxicity.
Furthermore, the large amount of biologic data outside
the world of gene expression microarrays should also
be integrated into these prediction models to further
refine and improve prediction sensitivity and specificity.
The combined application of these technologies and
techniques may yet realize the promise of effective
and individualized cancer therapy.
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